The latest price trends of serputinib/serpatinib in 2025

Selpercatinib is an innovative RET receptor tyrosine kinase (RET-TKI) inhibitor and a precision targeted therapy. The drug was originally developed by Lilly in the United States and is marketed in many countries around the world under the trade name Retevmo. It is used to treat patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other RET fusion-positive solid tumors driven by RET gene changes. With its breakthrough results in the field of precision medicine, seputinib is regarded as one of the representative drugs for RET pathway targeted therapy.

In terms of price, Septinib is already on the market in mainland China, but has not yet been included in the national medical insurance directory. The current market price is relatively high, and the price per box of 80mg*56 capsules is about RMB 10,000 or more. Since the original drug is produced by Eli Lilly and Company, costs and patent protection have kept prices high. In overseas markets, the European and American versions of original drugs are more expensive, ranging from 20,000 to more than 100,000 yuan per box, which is greatly affected by differences in exchange rates, tariffs and channels.

It is worth noting that the price of seputinib is gradually diverging. In Laos, Bangladesh and other places, generic versions have been launched, and their main ingredients and dosage specifications are consistent with the original drug. For example, a 40mg*120-capsule generic drug launched by a Lao pharmaceutical factory is priced at more than 2,000 yuan, which is more economical than the original drug. These products are legally available for purchase under the guidance of physicians in some international drug channels, providing patients with more affordable treatment options.

In general, the price fluctuations of seputinib are closely related to the place of origin, exchange rate and policy regulation. Its accessibility is increasing as generic versions become available around the world. In the future, if the drug is included in medical insurance or more imported versions are introduced, the price is expected to be further reduced, benefiting moreRET-positive patients.

Reference:https://en.wikipedia.org/wiki/Selpercatinib